Novel agonist of the tissue-protective erythropoietin (EPO) receptor, increasing FXN expression and EPOR phosphorylation

The first nonpeptidyl, selective activator of the tissue-protective EPOR/CD131 receptor

Antibiotic, being used as an antineoplastic agent and to induce diabetes in experimental animals

Metablite of the Streptomyces antibiotics streptothricin and streptolin

Potent natural modulator of human Toll-like receptor 7 (TLR7)

Novel activator of cellular ATG4B activity

Novel blocker of IL-17A binding to the IL-17A receptor (IL-17RA)

Novel inhibitor of the heterogeneous ribonuclear protein A18 (hnRNP A18)

Dual inhibitor of topoisomerase 1 and 2, inducing G(2) arrest in the absence of DNA damage. Inhibitor of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay

Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor

Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor

Novel covalent antagonist of hsSTING

Novel non-nucleotide STING agonist, demonstrating antitumor activity when dosed intratumorally in a syngeneic mouse model

Natural anti-feline infectious peritonitis virus (FIPV) agent, specifically targeting the 3CLpro of FIPV and inhibiting its replication

Novel RBP4 antagonist for treatment of Stargardt disease

Novel inhibitor of expression from canonical CREB response element-containing promoters

Natural inducer of G1 arrest in primary human esophageal epithelial cells but G2 arrest in immortalized cells

Novel human stem/progenitor cells proliferation activator, promoting survival and preserving stemness in human embryonic stem cells

Highly Potent and Selective Inhibitor of the Transcription Factor STAT5b

Novel cell-permeable selective STAT5a inhibitor prodrug, inhibiting tyrosine phosphorylation of STAT5a with selectivity over STAT5b in cultured human leukemia cells, and representing a valuable tool to define the non-redundant molecular functions of the t

Novel inhibitor of signal transducer and activator of transcription 3 (STAT3), inhibiting the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145

Novel inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo

Novel potent and selective inhibitor of STAT3

Novel inhibitor of STAT3, targeting SH2 domain

Novel inhibitor of STAT3 signaling pathway

Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity

Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR)

Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria

Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP

Novel tubulin-binding vascular disrupting agent (VDA)